PER	Hope
DIS	or
CON	Hype
REL	for
DEF	Personalized
ORG	Medicine
QUE	?
NIL	STANFORD
NIL	–
AND	During
DEF	the
IST	past
IST	several
CON	decades
NIL	,
CON	treatment
REL	for
DIS	a
CON	variety
AND	of
CON	conditions
NOW	has
EXS	begun
SUB	to
EXS	shift
REL	from
DIS	a
IST	“one
CON	size
ENS	fits
AND	all
NIL	”
CON	approach
REL	to
DIS	a
MOR	more
IST	personalized
CON	strategy
NIL	.
AND	As
DIS	a
CON	result
NIL	,
CON	patients
POS	can
IST	more
IST	often
EXS	be
EXS	matched
REL	to
DEF	the
TOP	best
CON	drug
REL	for
HAS	their
IST	genetic
CON	makeup
DIS	or
DEF	the
IST	exact
CON	subcategory
AND	of
HAS	their
CON	disease
NIL	.
PRX	This
ENS	enables
CON	physicians
SUB	to
EXS	avoid
AND	prescribing
DIS	a
CON	medication
NIL	(
DIS	or
DIS	a
CON	dosage
NIL	)
AND	that
POS	might
EXS	cause
IST	serious
CON	side
CON	effects
REL	in
IST	certain
CON	populations
NIL	.
REL	In
ALT	other
CON	words
NIL	,
AND	even
AND	among
CON	patients
AND	who
IST	apparently
NOW	have
DEF	the
IST	same
CON	disease
AND	and
CON	symptoms
NIL	,
DEF	the
CON	treatment
REL	for
AND	each
QUC	one
FUT	would
EXS	be
EXS	determined
REL	by
IST	various
IST	predictive
DIS	or
IST	prognostic
CON	tests
NIL	.
IST	Eventually
NIL	,
PRX	these
CON	tests
POS	could
EXS	extend
IST	even
REL	to
DEF	the
CON	sequencing
AND	of
DEF	the
CON	DNA
REL	in
DIS	an
IST	individual
CON	patient
AND	’s
CON	cancer
CON	cells
NIL	,
REL	for
CON	example
NIL	.
AND	But
NIL	,
SUB	while
PRX	this
IST	high-tech
CON	approach
POS	could
EXS	be
DIS	a
CON	boon
REL	to
CON	patients
NIL	,
PRO	it
POS	could
EXS	prove
EXS	detrimental
REL	to
CON	drug
CON	companies
AND	’
CON	bottom
CON	lines
NIL	.
DEF	The
CON	reasons
NOW	are
EXS	subtle
NIL	.
IST	Personalized
CON	drug
CON	therapy
NOW	uses
IST	biological
CON	indicators
EQU	,
DIS	or
CON	“biomarkers
NIL	”
NIL	–
AND	such
AND	as
CON	DNA
CON	sequences
DIS	or
DEF	the
CON	presence
DIS	or
CON	absence
AND	of
CON	drug
CON	receptors
NIL	–
AND	as
DIS	an
CON	indicator
AND	of
QUE	how
CON	patients
NEC	should
EXS	be
EXS	treated
NIL	,
AND	as
NIL	well
AND	as
SUB	to
EXS	estimate
DEF	the
CON	likelihood
AND	that
DEF	the
CON	intervention
FUT	will
EXS	be
IST	effective
NIL	.
PRX	This
CON	concept
NOW	is
NOT	not
IST	new
AND	:
PRO	it
NOW	has
EXT	been
EXS	known
REL	for
CON	decades
NIL	,
REL	for
CON	example
NIL	,
AND	that
CON	people
AND	who
NOW	have
DIS	a
IST	genetic
CON	deficiency
AND	of
DIS	an
CON	enzyme
EPS	called
CON	G6PD
POS	can
EXS	experience
IST	severe
AND	and
IST	precipitous
GEO	anemia
IMP	if
PRO	they
NOW	are
EXS	exposed
REL	to
IST	certain
CON	drugs
NIL	.
AND	Similarly
NIL	,
IST	ethnic
CON	groups
AND	and
CON	individuals
ENS	vary
IST	widely
REL	in
HAS	their
CON	ability
SUB	to
EXS	clear
CON	medications
REL	from
DEF	the
CON	bloodstream
NIL	,
EXS	owing
REL	to
CON	differences
REL	in
DEF	the
CON	activity
AND	of
DEF	the
CON	enzymes
SUB	that
EXS	metabolize
NIL	,
DIS	or
CON	degrade
NIL	,
CON	drugs
NIL	.
DST	That
NOW	is
EXS	important
SUB	because
EXS	low
CON	metabolizers
EXS	clear
IST	certain
CON	drugs
IST	slowly
COO	and
EXS	have
IST	more
CON	medication
REL	in
HAS	their
CON	systems
REL	for
IST	longer
CON	periods
AND	of
CON	time
AND	than
IST	high
CON	metabolizers
NIL	.
AND	Thus
NIL	,
DEF	the
CON	former
POS	might
EXS	be
IST	prone
REL	to
CON	overdose
NIL	,
COO	and
DEF	the
CON	latter
REL	to
IST	insufficient
CON	levels
AND	of
DEF	the
IST	same
CON	drug
NIL	.
IST	Prognostic
CON	biomarkers
NOW	have
EXS	begun
SUB	to
EXS	make
DIS	a
IST	big
CON	difference
REL	in
CON	cancer
CON	therapy
NIL	.
CON	Drugs
AND	such
AND	as
GEO	Erbitux
COO	and
GEO	Vectibix
ENS	work
XCL	only
REL	in
CON	tumors
EXG	containing
DEF	the
IST	normal
CON	version
AND	of
DIS	a
CON	gene
EPS	called
CON	KRAS
NIL	.
IMP	If
CON	mutations
AND	of
GEO	KRAS
NOW	are
EXS	present
NIL	,
DEF	the
CON	drugs
NOW	are
EXS	ineffective
NIL	.
